SECULAR TRENDS IN BASELINE CHARACTERISTICS, TREATMENT RETENTION AND RESPONSE RATES IN 17453 BIO-NAIVE PSORIATIC ARTHRITIS PATIENTS INITIATING TNFI-RESULTS FROM THE EUROSPA COLLABORATION.
Abstract: OP0220
Authors: S. N. Christiansen et al.
Key content:
Data on bio-naive patients with psoriatic arthritis starting a TNF inhibitor were collected prospectively from 15 European countries. Groups were defined according to time intervals as drug availability changed over time: Group A (1999–2008), group B (2009–2014), group C (2015–2018). A total of 17453 patients were analysed with 4069 being in group A, 7551 in group B and 5833 in group C. Patients in group A tended to be older, had a longer disease duration and had a higher disease activity at baseline. Retention rate was highest in group A, but the proportion of patients achieving DAS28 or DAPSA28 remission was lower after 6 and 12 months. Compared to group A, in group B and C patient age, disease duration and disease activity at the start of the first TNFi were decreased.
Relevance:
The data confirms a change in treatment habits over time: TNF inhibitors as the first biologic in PsA are started after a shorter disease duration resulting in higher remission rates, but in patients who do not adequately respond, options for switching to a different biologic or JAK seem to be used more frequently.
